staphylococcus aureus bacteremia
Conditions
Brief summary
PK Assessment: Establishment of correct cefadroxil doses through Monte Carlo simulations (serum concentrations > MIC for at least 50% of the day). PD Assessment: Therapeutic failure will be assessed as a composite endpoint of relapsing SAB, deep-seated infection with the same bacteria, switch to another antimicrobial regimen due to ad-verse events or failure to improve, attributable rehospitalization, or attributable mortality within 90 days of inclusion. Adverse Events (AE): Monitoring and re
Interventions
DRUGCefadroxil Sandoz 500 mg harde capsules
Sponsors
UZ Brussel
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PK Assessment: Establishment of correct cefadroxil doses through Monte Carlo simulations (serum concentrations > MIC for at least 50% of the day). PD Assessment: Therapeutic failure will be assessed as a composite endpoint of relapsing SAB, deep-seated infection with the same bacteria, switch to another antimicrobial regimen due to ad-verse events or failure to improve, attributable rehospitalization, or attributable mortality within 90 days of inclusion. Adverse Events (AE): Monitoring and re | — |
Countries
Belgium
Outcome results
None listed